AstraZeneca gastric cancer ADC meets overall-survival goal in Phase 3
AstraZeneca said sonesitatug vedotin improved overall survival versus investigator’s choice in CLARITY-Gastric01 for CLDN18.2-positive advanced gastric and related cancers. Progression-free survival did not reach statistical significance. Hazard ratios were not released.
What's new
- New headline Was: “AstraZeneca's stomach cancer drug clears bar for extending overall survival in late-stage study”
- Our desk filed its story
- New headline Was: “Amgen drug combined with immunotherapy extends survival in lung cancer trial”